StockData
Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc. (AUPH) shareholders

AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 13/3059% below fair value
$15.40−0.08 (-0.52%)

Close on Nov 17, 2026Market cap $2.06BP/E 6.7Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
58.3%
78M of 134M shares
Institutional holders
281
49 new, 24 sold out
Net institutional buying
5M
In Q2 2026
Insider trades, 12 months
11 buys · 3 sales
Net bought $24.41M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Tang Capital Management, LLC
Joint filing with Kevin Tang (10.00%), Tang Capital Partners, LP (5.60%)
13,044,10610.00%13D (active) amendmentJun 2, 2026
Kevin Tang
Joint filing with Tang Capital Management, LLC (7.30%)
10,029,5007.30%13D (active) amendmentFeb 28, 2025
BlackRock, Inc.8,921,0496.20%13G (passive) amendmentDec 31, 2023

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of AUPHValueChange% of portfolio
Tang Capital Management LLC13,044,1069.73%$221.36M+814,60610.05%
BlackRock, Inc.8,193,0856.11%$139.04M+347,5640.00%
Goldman Sachs Group Inc5,619,4014.19%$95.36M+4,185,8930.01%
NEA Management Company, LLC3,969,8342.96%$67.37M–4.24%
Two Sigma Investments, LP3,467,5142.59%$58.84M+38,8090.04%
Arrowstreet Capital, Limited Partnership3,264,0622.44%$55.39M−20,3060.02%
State Street Corp2,589,6151.93%$43.95M+62,5160.00%
Morgan Stanley2,308,2441.72%$39.17M+75,6960.00%
Marshall Wace, Llp2,044,0071.53%$34.69M+169,4100.03%
Geode Capital Management, LLC1,701,1521.27%$28.86M+165,1430.00%
Renaissance Technologies LLC1,548,0351.16%$26.27M−115,8000.04%
D. E. Shaw & Co., Inc.1,408,4561.05%$23.90M−164,5270.01%
Vanguard Portfolio Management LLC1,359,0281.01%$23.06M+102,6670.00%
Jacobs Levy Equity Management, Inc1,231,5160.92%$20.90M+134,3270.08%
Jupiter Asset Management Ltd1,094,4750.82%$18.57M+291,0560.09%
Lsv Asset Management1,079,4470.81%$18.32M+39,8710.03%
Nomura Holdings Inc978,6020.73%$16.61M+9,6920.02%
Aqr Capital Management LLC948,7510.71%$16.10M−590.01%
Northern Trust Corp863,5670.64%$14.65M+39,4620.00%
Nuveen, LLC812,9150.61%$13.80M+159,4910.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202628178M58.3%49 / 10580 / 2411M6M
Q1 202626074M55.2%40 / 10471 / 2910M6M
Q4 202525673M54.2%45 / 8982 / 2912M6M
Q3 202524267M49.7%47 / 6291 / 2015M8M
Q2 202521959M44.1%34 / 6963 / 287M11M
Q1 202521463M46.8%38 / 6759 / 2111M6M
Q4 202420059M43.7%38 / 6351 / 197M8M
Q3 202418359M44.1%31 / 5246 / 1619M7M
Q2 202417157M42.2%25 / 5747 / 316M8M
Q1 202417859M43.8%27 / 4762 / 399M6M
Q4 202319156M41.5%22 / 6064 / 2612M6M
Q3 202319851M38.1%24 / 6949 / 238M7M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

178 funds held AUPH in Q2 2026, 59% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of AUPHValue% of fundAs of
iShares Russell 2000 ETF3,062,4022.29%$51.97M0.06%Jun 30, 2026
Fidelity Small Cap Index Fund1,303,1090.97%$19.39M0.06%Jul 31, 2026
iShares Russell 2000 Growth ETF1,101,3240.82%$18.69M0.12%Jun 30, 2026
iShares Biotechnology ETF800,9330.60%$13.59M0.15%Jun 30, 2026
Vanguard Russell 2000 Index Fund613,2580.46%$9.40M0.05%May 31, 2026
Goldman Sachs U.S. Tax-Managed Equity Fund541,4430.40%$9.19M0.19%Jun 30, 2026
Nuveen Quant Small Cap Equity Fund480,6500.36%$7.15M0.18%Jul 31, 2026
Vanguard Health Care Index Fund336,0350.25%$5.15M0.03%May 31, 2026
Goldman Sachs Small Cap Value Insights Fund334,6850.25%$4.98M0.38%Jul 31, 2026
Fidelity Enhanced Small Cap Core ETF321,8690.24%$5.46M0.09%Jun 30, 2026
Goldman Sachs Small Cap Equity Insights Fund304,1180.23%$4.53M0.45%Jul 31, 2026
Schwab Small-Cap Index Fund288,4130.22%$4.29M0.06%Jul 31, 2026
Avantis U.S. Small Cap Equity ETF241,1570.18%$3.70M0.13%May 31, 2026
Federated Hermes MDT Small Cap Growth Fund237,7980.18%$3.54M0.42%Jul 31, 2026
Master Small Cap Index Series216,1790.16%$3.67M0.06%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Kevin TangChief Executive Officer, Director, 10% owner13,044,1069.73%Jun 2, 2026
Peter GreenleafChief Executive Officer, Director1,840,3791.37%Mar 3, 2026
Stephen P. RobertsonChief Legal Officer576,9810.43%Nov 16, 2026
Ryan ColeChief Operating Officer116,1440.09%May 20, 2026
Michael S. HearneChief Financial Officer116,1440.09%May 20, 2026
Greg KeenanSVP, Chief Medical Officer154,4490.12%Mar 10, 2026
Joseph M. MillerChief Financial Officer576,4210.43%Mar 3, 2026
Matthew Maxwell DonleyChief Operating Officer680,2990.51%Mar 3, 2026
Kathleen GoetzDirector––Jun 8, 2026
Craig A. JohnsonDirector14,5920.01%Jun 8, 2026
Jeffrey Allen BaileyDirector22,7750.02%Jun 8, 2026
Tina Susan NovaDirector––Jun 8, 2026
Karen L. SmithDirector24,8070.02%Nov 25, 2024
David R.W. JayneDirector56,4990.04%Nov 25, 2024
Jill LeversageDirector26,4530.02%Nov 25, 2024
Capital Management Llc Tang10% owner––Jun 2, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Stephen P. Robertson
Chief Legal Officer
Nov 13, 2026Sale−11,867$15.97$189.52K576,981
Stephen P. Robertson
Chief Legal Officer
Sep 10, 2026Sale−11,939$15.95$190.43K588,848
Stephen P. Robertson
Chief Legal Officer
Aug 21, 2026Sale−20,975$16.97$355.95K600,787
Kevin Tang
Chief Executive Officer, Director, 10% owner
Jun 2, 2026Buy+206,005$15.28$3.15M13,044,106
Kevin Tang
Chief Executive Officer, Director, 10% owner
Jun 1, 2026Buy+99$15.34$1.52K12,838,101
Kevin Tang
Chief Executive Officer, Director, 10% owner
Jun 1, 2026Buy+343,521$15.28$5.25M12,838,002
Kevin Tang
Chief Executive Officer, Director, 10% owner
May 29, 2026Buy+262,682$15.31$4.02M12,494,481
Kevin Tang
Chief Executive Officer, Director, 10% owner
May 29, 2026Buy+2,299$15.35$35.29K12,231,799
Ryan Cole
Chief Operating Officer
May 18, 2026Award+116,144––116,144
Stephen P. Robertson
Chief Legal Officer
May 18, 2026Award+115,541––621,402
Michael S. Hearne
Chief Financial Officer
May 18, 2026Award+116,144––116,144
Greg Keenan
SVP, Chief Medical Officer
Mar 6, 2026Tax withholding−8,069$14.32$115.55K154,449
Kevin Tang
Director
Mar 3, 2026Buy+184,208$14.22$2.62M12,229,500
Stephen P. Robertson
EVP, General Counsel
Mar 2, 2026Tax withholding−36,525$14.21$519.02K505,861
Joseph M. Miller
Chief Financial Officer
Mar 2, 2026Tax withholding−37,511$14.21$533.03K576,421
Peter Greenleaf
Chief Executive Officer, Director
Mar 2, 2026Tax withholding−100,890$14.21$1.43M1,840,379
Kevin Tang
Director
Mar 2, 2026Buy+115,792$14.21$1.65M12,045,292
Kevin Tang
Director
Mar 2, 2026Buy+83,561$14.33$1.20M11,929,500
Matthew Maxwell Donley
Chief Operating Officer
Mar 2, 2026Tax withholding−40,761$14.21$579.21K680,299
Stephen P. Robertson
EVP, General Counsel
Feb 27, 2026Award+59,090––542,386
Joseph M. Miller
Chief Financial Officer
Feb 27, 2026Award+57,229––613,932
Peter Greenleaf
Chief Executive Officer, Director
Feb 27, 2026Award+196,403––1,941,269
Kevin Tang
Director
Feb 27, 2026Buy+300,000$13.90$4.17M11,629,500
Kevin Tang
Director
Feb 27, 2026Buy+1,600$14.38$23.01K11,845,939
Kevin Tang
Director
Feb 27, 2026Buy+214,839$14.12$3.03M11,844,339
Greg Keenan
SVP, Chief Medical Officer
Feb 27, 2026Award+40,586––162,518
Matthew Maxwell Donley
Chief Operating Officer
Feb 27, 2026Award+58,160––721,060
Stephen P. Robertson
EVP, General Counsel
Feb 20, 2026Tax withholding−34,638$14.40$498.79K483,296
Joseph M. Miller
Chief Financial Officer
Feb 20, 2026Tax withholding−32,424$14.40$466.91K556,703
Matthew Maxwell Donley
Chief Operating Officer
Feb 20, 2026Tax withholding−32,901$14.40$473.77K662,900
Peter Greenleaf
Chief Executive Officer, Director
Feb 20, 2026Tax withholding−100,171$14.40$1.44M1,744,866
Greg Keenan
SVP, Chief Medical Officer
Feb 2, 2026Tax withholding−11,552$14.53$167.85K121,932
Stephen P. Robertson
EVP, General Counsel
Jan 2, 2026Tax withholding−40,385$15.95$644.14K517,934
Stephen P. Robertson
EVP, General Counsel
Jan 2, 2026Award+48,558––557,434
Peter Greenleaf
Chief Executive Officer, Director
Jan 2, 2026Award+165,384––1,954,329
Peter Greenleaf
Chief Executive Officer, Director
Jan 2, 2026Tax withholding−113,169$15.95$1.81M1,845,037
Joseph M. Miller
Chief Financial Officer
Jan 2, 2026Tax withholding−40,161$15.95$640.57K589,127
Joseph M. Miller
Chief Financial Officer
Jan 2, 2026Award+49,038––626,399
Matthew Maxwell Donley
Chief Operating Officer
Jan 2, 2026Award+54,166––734,631
Matthew Maxwell Donley
Chief Operating Officer
Jan 2, 2026Tax withholding−42,787$15.95$682.45K695,801
Jeffrey Allen Bailey
Director
Nov 21, 2025Tax withholding−2,716$15.68$42.59K22,775
Craig A. Johnson
Director
Nov 21, 2025Tax withholding−6,039$15.68$94.69K14,592
Kevin Tang
Director
Aug 5, 2025Buy+200,000$11.68$2.34M11,329,500
Kevin Tang
Director
Aug 4, 2025Buy+100,000$11.34$1.13M11,129,500
Greg Keenan
Chief Medical Officer
Aug 1, 2025Sale−20,000$10.50$210.00K133,484
Kevin Tang
Director
Aug 1, 2025Buy+1,000,000$10.12$10.12M11,029,500
Greg Keenan
Chief Medical Officer
Mar 7, 2025Sale−8,305$8.23$68.35K153,484
Matthew Maxwell Donley
Chief Operating Officer
Mar 4, 2025Sale−58,991$7.92$467.21K680,465
Stephen P. Robertson
EVP, General Counsel
Mar 4, 2025Sale−57,607$7.92$456.25K509,276
Kevin Tang
Director
Mar 4, 2025Buy+148,038$8.00$1.18M9,429,500
Kevin Tang
Director
Mar 4, 2025Buy+500,000$7.92$3.96M9,929,500
Kevin Tang
Director
Mar 4, 2025Buy+100,000$8.09$809.00K10,029,500
Joseph M. Miller
Chief Financial Officer
Mar 4, 2025Sale−56,154$7.92$444.74K577,361
Peter Greenleaf
Chief Executive Officer, Director
Mar 4, 2025Sale−164,947$7.92$1.31M1,788,945
Matthew Maxwell Donley
Chief Operating Officer
Mar 3, 2025Award+135,567––805,358
Matthew Maxwell Donley
Chief Operating Officer
Mar 3, 2025Sale−65,902$8.00$527.22K739,456
Greg Keenan
Chief Medical Officer
Mar 3, 2025Sale−12,239$8.00$97.91K161,789
Stephen P. Robertson
EVP, General Counsel
Mar 3, 2025Award+102,406––631,755
Stephen P. Robertson
EVP, General Counsel
Mar 3, 2025Sale−64,872$8.00$518.98K566,883
Kevin Tang
Director
Mar 3, 2025Buy+351,962$8.02$2.82M9,281,462

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
6.44%
7M shares short
Days to cover
10.3
At 1M shares a day
Change since last report
-8.3%
From 8M shares
Short volume, 20 days
35.6%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Aurinia Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 8,000 shares on Oct 1, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Stephen P. Robertson
Officer
Aug 21, 202647,000$719.10KAug 21, 2026Performance Stock Units
Gregory Keenan
Former Affiliate
Jun 5, 20269,593$158.49KJun 5, 2026Exercise of Options Under a Registered Plan
Gregory Keenan
Former Affiliate
Jun 4, 202625,000$408.44KJun 4, 2026Exercise of Options Under a Registered Plan
Gregory Keenan
Officer
Jun 2, 202625,000$54.10MJun 2, 2026Exercise of options under a registered plan
Peter Greenleaf
Former Affiliate
May 11, 20263,136,201$49.68MMay 11, 2026Exercise of options under a registered plan
Matthew Maxwell Donley
Former Affiliate
May 11, 2026717,688$11.37MMay 11, 2026Exercise of options under a registered plan
Joseph M. Miller
Former Affiliate
May 11, 2026500,503$7.93MMay 11, 2026Exercise of options under a registered plan

See a number that looks wrong?